Depression, Anxiety
Conditions
Brief summary
The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance). There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment. Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine
Interventions
DRUGLysergic Acid Diethylamide (LSD)
one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department
Sponsors
Tatiana Aboulafia Brakha
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* ongoing psychotherapy with a certified psychotherapist, anxiety disorder or depression resistant to usual treatments, agreement to stop necessary medication
Exclusion criteria
* Exclusion: psychotic or bipolar disorder, high suicidal risk, severe cardiovascular disease, severe liver disease, neurological disease of the central nervous system, pregnancy and breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Salivary oxytocin | the day of treatment administration (one day) | oxytocin sampled in the saliva |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Self-reported intensity of mystical experience | The 1 day of treatment administration | Assessed with the self-report Mystical experience Questionnaire (MEQ-30) with total man score ranging from 0 to 5, with higher scores indicating higher intensity of mystical experience |
| Self-reported intensity of Connectedness | The 1 day of treatment administration | Assessed with the self-report Watts Connectedness Scale,total mean score ranging from 0 to 100, with higher scores indicating higher connectedess |
| Self-reported symptoms of anxiety (STAI-T) | over 6 months | State-Trait Anxiety Inventory (trait), total scores ranging from 20 to 80, higher scores indicating higher anxiety |
| Self-reported depressive symptoms (BDI-II) | over 6 months | Beck Depresion Inventory-II, total scores ranging from 0 to 63, higher scores indicating higher depressive symptoms |
Countries
Switzerland
Outcome results
None listed